Killian Meara

Eric Fromhart, co-founder and chief growth officer at Aventi Health, discusses how pharmacies can use 340B to increase profits and how they can avoid any potential risks when participating in the program.

Brian Rakers, senior vice president of distribution and member support at Pharmacists Mutual Insurance Group, talked cybersecurity during a session at AAP 2024.

In an interview at AAP 2024, Douglas Hoey, CEO of NCPA, talked about changing the pharmacy payment model and deceptive practices being employed by PBMs.

Joe McKamey, general manager at Marcrom’s Pharmacy in Manchester, Tennessee, talks about why pharmacies should open their own Medicare-focused insurance agency and what steps and preparations they can take to ensure a successful launch and operation.

Kathy Campbell, PharmD, pharmacist and patient advocate at Medicap Pharmacy in Owassa, Oklahoma, and CEO of DrKathy Health, discusses the unique value that a wellness-focused pharmacy offers compared to traditional models.

Eric Fromhart, co-founder and chief growth officer at Aventi Health, talked about the importance of the 340B drug pricing program at the 2024 AAP annual conference.

Drug Topics sat down with Douglas Hoey, CEO of NCPA, at the 2024 AAP annual conference to discuss how independent pharmacies are doing so far this year.

This year’s conference, which is being held April 4 to 6 in San Diego, California, features talks from industry experts on developments in the pharmacy field, actionable skills, and informative CE sessions.

Priovant Therapeutics said that it intends to initiate a phase 3 program of brepocitinib in the second half of this year.

Rejoyn from Otsuka Pharmaceutical and Click Therapeutics is a 6-week program that helps enhance cognitive control of emotions through brief therapy lessons and training exercises.

The can’t-miss event on April 13 features speakers and CE sessions focused on elevating patient-centric care.

The approval of vadadustat (Vafseo) from Akebia Therapeutics was based on data from the phase 3 INNO2VATE program.

Tenofovir alafenamide was originally approved by the FDA in 2016 to treat adults with chronic HBV infection with compensated liver disease and in 2022 to treat pediatric patients aged 12 years and older.

At APhA 2024, 2 posters looked into how collaboration between physicians and community pharmacists is crucial when it comes to opioid prescriptions, and current opioid use patterns among older adults.

Two posters presented at APhA 2024 examined how the COVID-19 pandemic impacted pharmacists and their work.

Posters presented at the APhA 2024 Annual Meeting and Exposition discussed pharmacist barriers in pediatric immunizations, a novel meningococcal vaccine, and the need for inpatient reviews of vaccination history.

The Partnership for Safe Medicines found several product listings on Etsy that are designed to mimic regulated pharmaceuticals.

Jeffrey Reese, president at Reese Pharmaceutical, discusses what sets ColoTest apart from other at-home colorectal cancer screening tests.

Medication therapy management can also increase the likelihood of using statins in this population.

Results from a meta-analysis on the side of effects of the psychedelic psilocybin were presented at the 2024 American Pharmacists Association Annual Meeting & Exposition.

Rilpivirine (Edurant Ped) effectively suppresses the HIV-1 virus in pediatric patients with HIV-1 RNA less than or equal to 100,000 copies/mL in combination with other antiretroviral therapies.

Aprocitentan (TRYVIO) from pharmaceutical company Idorsia demonstrated statistically significant and clinically meaningful reductions in blood pressure in combination with other antihypertensive therapies.

The biotechnology company’s recombinant spike protein-based vaccine demonstrated an efficacy of 88% after 40 days, 82% after 120 days, and 77% after 180 days during the PREVENT-19 trial.

Despite the significant growth of biosimilars, their adoption across various therapeutic areas has remained slow.

The approval was based on data from the phase 1/2 TRANSCEND CLL 004 study, in which the CAR T cell therapy demonstrated statistically significant complete response rates.

The approval, awarded to Madrigal Pharmaceuticals, was based on phase 3 data demonstrating that resmetirom achieved broad treatment effects in patients with MASH with liver fibrosis.

With growing concerns around opioid use disorder, interventional pain management for patients with cancer can provide effective relief without the side effects associated with medication.

Cybin’s proprietary deuterated psilocybin analog, CYB003, provided robust and sustained improvements in depression symptoms in a phase 2 study.

A panel discussion at the Outcomes 2024 SYNC National Conference touched upon many important themes in community pharmacy, including the evolving role of pharmacists, emerging tech, and key challenges going forward.

Mind Medicine’s lysergide d-tartrate (MM120) demonstrated statistically significant and clinically meaningful improvements in anxiety symptoms in a phase 2b study.